Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

JAMA Intern Med. 2021 Nov 1;181(11):1530-1533. doi: 10.1001/jamainternmed.2021.3779.

Matthew S Krantz¹, Jason H Kwah², Cosby A Stone Jr¹, Elizabeth J Phillips^{3

4}, Gilbert Ortega⁵, Aleena Banerji^{6

7}, Kimberly G Blumenthal^{6

7

8

9}

¹ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Yale School of Medicine, Section of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, New Haven, Connecticut.
³ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
⁵ Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
⁶ Harvard Medical School, Boston, Massachusetts.
⁷ Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston.
⁸ Mongan Institute, Massachusetts General Hospital.
⁹ Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston.

Abstract

This case series study examines the safety of second doses of messenger RNA COVID-19 vaccines after first-dose allergic reactions.